Drugs & Aging

, Volume 17, Issue 5, pp 363–384 | Cite as

Antipsychotic-Induced Movement Disorders in the Elderly

Epidemiology and Treatment Recommendations
  • Michael P. Caligiuri
  • Dilip V. Jeste
  • Jonathan P. Lacro
Review Article


We reviewed the epidemiological aspects of antipsychotic-induced movement disorders as they pertain to older patients. The incidence and prevalence of drug-induced parkinsonism and tardive dyskinesia (TD) are significantly greater in the older patient than in the younger patient whereas akathisia seems to occur evenly across the age spectrum and dystonia is uncommon among older patients. The literature on risk factors associated with treatment-emergent movement disorders is highly variable. Treatment practices vary across the age range and the interaction between age and antipsychotic dosage confounds our understanding of the relative importance of treatment-related risk factors. However, there is general agreement that pre-existing extrapyramidal signs (EPS) increase the vulnerability of the patient to developing significant drug-induced movement disorders. Elderly patients with dementia are at greater risk than patients without dementia for persistent drug-induced EPS.

Management of drug-induced movement disorders in the older patient requires careful consideration of the contraindications imposed by such agents as anticholinergics and β-blockers. At present, well-controlled double-blind studies of second-generation antipsychotics such as clozapine, risperidone, olanzapine or quetiapine for reducing the risk of treatment-emergent movement disorders in the elderly have not been published. However, open-label studies of atypical antipsychotics demonstrate a markedly lower incidence of both EPS and TD compared with conventional antipsychotic treatment in the elderly. There is emerging literature in support of atypical antipsychotics for the treatment of existing drug-induced movement disorders. More controversial is the use of adjunctive antioxidants in newly treated patients who are vulnerable to drug-induced movement disorders. While the evidence is mixed in support of antioxidants for the treatment of TD, the possibility remains that prophylactic use of antioxidants may help reduce the incidence of TD.

The development of a drug-induced movement disorder often reduces the quality of life in an elderly patient. Effective pharmacological management requires cooperation from the patient and family, which can be fostered early in the patient’s care through proper informed consent. The risks and benefits of antipsychotic treatment in the elderly patient need to be communicated to the patient and family. At the present time, there is no consistently effective treatment for patients with TD once it develops. Therefore, attention should focus on its prevention and close monitoring.


  1. 1.
    Miller LG, Jankovic J. Drug-induced movement disorders: an overview. In: Joseph AB, Young RR, editors. Movement disorders in neurology and neuropsychiatry. Boston: Blackwell Scientific Publications, 1992: 5–32Google Scholar
  2. 2.
    Jeste DV, Naimark D. Medication-induced movement disorders. In: Tasman A, Kay J, Lieberman J, editors. Psychiatry. Vol. 2. Philadelphia: WB Saunders, 1996: 1304–54Google Scholar
  3. 3.
    Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psycho-pharmacol 1998; 13Suppl. 3: S49–57CrossRefGoogle Scholar
  4. 4.
    Diederich NJ, Goetz CG. Drug-induced movement disorders. Neurologic Clin 1998; 16: 125–39CrossRefGoogle Scholar
  5. 5.
    Jeste DV, Alexopoulos GS, Bartels SJ, et al. Consensus statement on the upcoming crisis in geriatric mental health. Arch Gen Psychiatry 1999; 56: 848–53PubMedCrossRefGoogle Scholar
  6. 6.
    Hornykiewicz O. Dopamine changes in the aging human brain: functional considerations. In: Agnoli A, Crepaldi G, Spano PF, et al., editors. Aging brain and ergot alkaloids. Vol. 23. New York: Raven Press, 1983: 9–14Google Scholar
  7. 7.
    Roth GS. Brain dopaminergic and opiate receptors and responsiveness during aging. In: Agnoli A, Crepaldi G, Spano PF, et al., editors. Aging brain and ergot alkaloids. Vol. 23. New York: Raven Press, 1983: 53–60Google Scholar
  8. 8.
    Volkow ND, Wang GJ, Fowler JS, et al. Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol 1998; 44: 143–7PubMedCrossRefGoogle Scholar
  9. 9.
    Zhang L, Roth GS. The effect of aging on rat striatal D1 receptor mRNA-containing neurons. Neurobiol Aging; 1997; 18: 251–5PubMedCrossRefGoogle Scholar
  10. 10.
    Stewart RB. Polypharmacy in the elderly: a fait accompli? DICP: Ann Pharmacother 1990; 24: 321–3Google Scholar
  11. 11.
    Scarpace PJ. Decreased beta-adrenergic responsiveness during senescence. Fed Proc 1986; 45: 51–4PubMedGoogle Scholar
  12. 12.
    Maletta G, Mattox KM, Dysken M. Guidelines for prescribing psychoactive drugs in the elderly: part I. Geriatrics 1991; 46: 40–7PubMedGoogle Scholar
  13. 13.
    Triggs EJ, Nation RL. Pharmacokinetics in the aged: a review. J Pharmacokinet Biopharmaceut 1975; 3: 387–418CrossRefGoogle Scholar
  14. 14.
    Williams L, Lowenthal DT. Drug therapy in the elderly. South Med J 1992; 85: 127–31PubMedCrossRefGoogle Scholar
  15. 15.
    Cherry KE, Morton MR. Drug sensitivity in older adults: the role of physiological and pharmacokinetic factors. Int J Aging Hum Devel 1989; 28: 159–74CrossRefGoogle Scholar
  16. 16.
    Ereshefsky L, Tran-Johnson T, Davis CM, et al. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine — new data and review. Clin Chem 1988; 34: 863–80PubMedGoogle Scholar
  17. 17.
    Avorn J, Gurwitz J. Principles of pharmacology. In: Cassel K, Riesenberg D, Sorenson L, et al., editors. Geriatric medicine. 2nd ed. New York: Springer Verlag, 1990: 66–77Google Scholar
  18. 18.
    Stevenson IH, Hosie J. Pharmacokinetics in the elderly. In: O’Malley K, Waddington JL, editors. Therapeutics in the elderly. New York: Elsevier Science, Biomedical Division, 1985: 35–40Google Scholar
  19. 19.
    Dahl SG. Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 1986; 11: 36–61PubMedCrossRefGoogle Scholar
  20. 20.
    Cohen BM, Summer BR. Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8: 336–9PubMedGoogle Scholar
  21. 21.
    Forsman A, Ohman R. Applied pharmacokinetics of haloperidol in man. CurrTherap Res 1977; 21: 396–411Google Scholar
  22. 22.
    Yesavage JA. Psychotropic blood levels: a guide to clinical response. J Clin Psychiatry 1986; 47Suppl. 9: 16–9PubMedGoogle Scholar
  23. 23.
    Reidenberg MM, Levy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23: 371–4PubMedGoogle Scholar
  24. 24.
    Waddington JL, O’Boyle KM, Molloy AG, et al. Neurotransmitter receptors and ageing: dopamine/neuroleptic receptors, involuntary movements and the disease process of schizophrenia. In: O’Malley K, Waddington JL, editors. Therapeutics in the elderly. New York: Elsevier Science, Biomedical Division, 1985: 63–76Google Scholar
  25. 25.
    Volkow ND, Logan J, Fowler JS, et al. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000; 157: 75–80PubMedCrossRefGoogle Scholar
  26. 26.
    Ereshefsky L, Tran-Johnson TK, Watanabe MD. Clinical frontiers: pathophysiologic basis for schizophrenia and the efficacy of antipsychotics. Clin Pharm 1990; 9: 682–707PubMedGoogle Scholar
  27. 27.
    Morgan DG, May PC, Finch CE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc 1987; 35: 334–45PubMedGoogle Scholar
  28. 28.
    Raja M. Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 1998; 19(1): 57–72PubMedCrossRefGoogle Scholar
  29. 29.
    Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991; 148: 85–9PubMedGoogle Scholar
  30. 30.
    Ebadi M, Srinivasan SK. Pathogenesis, prevention, and treatment of neuroleptic-induced movement disorders. Pharmacol Rev 1995; 47: 575–604PubMedGoogle Scholar
  31. 31.
    Remington GJ. The long-term treatment of schizophrenia. Can J Psychiatry 1995; 40 (3 Suppl. 1): S3–4PubMedGoogle Scholar
  32. 32.
    Van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ (Clin Res Ed) 1999; 319: 623–6CrossRefGoogle Scholar
  33. 33.
    Tune L, Coyle JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981; 75: 9–15PubMedCrossRefGoogle Scholar
  34. 34.
    Kucharski LT, Alexander P, Tune L, et al. Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology 1984; 82: 194–8PubMedCrossRefGoogle Scholar
  35. 35.
    Keepers GA, Ganzini L. Clinical aspects of neuroleptic-induced dystonia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press, 1997: 381–94Google Scholar
  36. 36.
    American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154: Suppl.: 1–63Google Scholar
  37. 37.
    Jipson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998; 32: 215–28CrossRefGoogle Scholar
  38. 38.
    Tandon R, Harrington E, Zorn SH. Ziprasidone: a novel anti-psychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159–77Google Scholar
  39. 39.
    King DJ, Link CGG, Kowalcyk B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137: 139–46PubMedCrossRefGoogle Scholar
  40. 40.
    Moore P. Handbook of botulinum toxin treatment. Cambridge: Blackwell Science Ltd, 1995Google Scholar
  41. 41.
    Chatterjee A, Gordon MF, Giladi N, et al. Botulinum toxin in the treatment of tardive dystonia. J Clin Psychopharmacol 1997; 17: 497–8PubMedCrossRefGoogle Scholar
  42. 42.
    Tarsey D, Kaufman D, Sethi KD, et al. An open-label study of botulinum toxin A for treatment of tardive dystonia. Clin Neuropharmacol 1997; 20: 90–3CrossRefGoogle Scholar
  43. 43.
    Kaanovskay P, Streitovaa H, Bareas M, et al. Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect. Mov Disord 1999; 14: 886–8CrossRefGoogle Scholar
  44. 44.
    Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double-blind, placebo-controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998; 64: 13–7PubMedCrossRefGoogle Scholar
  45. 45.
    Brashear A, Ambrosius WT, Eckert GJ, et al. Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov Disord 1998; 13: 158–61PubMedCrossRefGoogle Scholar
  46. 46.
    Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 1999; 246: 265–74PubMedCrossRefGoogle Scholar
  47. 47.
    Sachdev P. The epidemiology of drug induced akathisia: part II. Chronic, tardive, and withdrawal akathisia. Schizophren Bull 1995; 21(3): 451–61CrossRefGoogle Scholar
  48. 48.
    Crane GE, Naranjo EK, Chase C. Motor disorders induced by neuroleptics: a proposed new classification. Arch Gen Psychiatry 1971; 24: 179–84PubMedCrossRefGoogle Scholar
  49. 49.
    Barnes TR, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–8PubMedCrossRefGoogle Scholar
  50. 50.
    Sachdev P. Akathisia and restless legs. Cambridge: Cambridge University Press, 1995CrossRefGoogle Scholar
  51. 51.
    Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233–46PubMedCrossRefGoogle Scholar
  52. 52.
    McManus DQ, Arvanitis LA, Kowalcyk BB, et al. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999; 60: 292–8PubMedCrossRefGoogle Scholar
  53. 53.
    Tollefson GD, Beasley Jr CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154(9): 1248–54PubMedGoogle Scholar
  54. 54.
    Sachdev P. Research diagnostic criteria for drug-induced akathisia: conceptualization, rationale, and proposal. Psycho-pharmacology 1994; 114: 181–6Google Scholar
  55. 55.
    Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia: a systemic investigation of an objective sign of acute akathisia. Psychopharmacology 1983; 82: 95–101CrossRefGoogle Scholar
  56. 56.
    Sandyk R, Kay SR. Relationship of neuroleptic-induced akathisia to drug-induced parkinsonism. Ital J Neuro Sci 1990; 11: 439–42Google Scholar
  57. 57.
    Burke RE, Kang UJ, Jankovic J, et al. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157–75PubMedCrossRefGoogle Scholar
  58. 58.
    Gardos G, Teicher MH, Lipinski Jr JF, et al. Quantitative assessment of psychomotor activity in patients with neuroleptic induced akathisia. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 27–37PubMedCrossRefGoogle Scholar
  59. 59.
    Hunter R, Earl CJ, Thornicroff S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc R Soc Med 1964; 57: 758–62PubMedGoogle Scholar
  60. 60.
    Munetz MR, Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry 1982; 23: 345–52PubMedCrossRefGoogle Scholar
  61. 61.
    Ayd FJ. A survey of drug induced extrapyramidal reactions. JAMA 1961; 175: 1054–60PubMedCrossRefGoogle Scholar
  62. 62.
    Adler LA, Peselow E, Rosenthal M, et al. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993; 29: 283–6PubMedGoogle Scholar
  63. 63.
    Burke RE. Tardive akathisia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press, 1997: 409–27Google Scholar
  64. 64.
    Adler LA, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: a review. Psychopharmacology (Berl) 1989; 97: 1–11CrossRefGoogle Scholar
  65. 65.
    Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10: 12–21PubMedCrossRefGoogle Scholar
  66. 66.
    Lipinsky JF, Zubenco GS, Barreira P, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983; II: 685–6CrossRefGoogle Scholar
  67. 67.
    Hermesch H, Molcho A, Munitz H. Successful propranolol therapy for neuroleptic-induced akathisia resistant to anticholinergic and benzodiazepine drugs. Clin Neuropharmacol 1988; 11: 369–72CrossRefGoogle Scholar
  68. 68.
    Kramer MS, Gorkin RA, DiJohnson C. Treatment of neuroleptic-induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989; 11: 107–19PubMedGoogle Scholar
  69. 69.
    Kramer MS, Gorkin RA, Di Johnson C, et al. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind placebo-controlled study. Biol Psychiatry 1988; 24: 823–7PubMedCrossRefGoogle Scholar
  70. 70.
    Dumon JP, Catteau J, Lanvin F, et al. Randomized, double-blind, cross-over, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149: 647–50PubMedGoogle Scholar
  71. 71.
    Levin H, Chengappa KN, Kambhampati RK, et al. Should chronic treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53: 248–51PubMedGoogle Scholar
  72. 72.
    Gerstman BB, Jolson HM, Bauer M, et al. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol 1996; 49: 809–15PubMedCrossRefGoogle Scholar
  73. 73.
    Ried LD, McFarland BH, Johnson RE, et al. Beta-blockers and depression: the more the murkier? Ann Pharmacother 1998; 32: 699–708PubMedCrossRefGoogle Scholar
  74. 74.
    Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 1978; 135: 1232–3PubMedGoogle Scholar
  75. 75.
    Kutcher SP, MacKenzie S, Galarraga W, et al. Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 823–4PubMedGoogle Scholar
  76. 76.
    Bartels M, Heide K, Mann K, et al. Treatment of akathisia with lorazepam: an open clinical trial. Psychopharmacology 1987; 20: 51–3Google Scholar
  77. 77.
    Adler LA, Angrist B, Peselow E, et al. Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1985; 5: 164–6PubMedCrossRefGoogle Scholar
  78. 78.
    Miller LG, Jankovic J. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J 1990; 83: 525–32PubMedCrossRefGoogle Scholar
  79. 79.
    Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995; 167: 483–6PubMedCrossRefGoogle Scholar
  80. 80.
    Poyurovsky M, Fuchs C, Weizman A. Low-dose mianserine in the treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 1998; 18: 253–4PubMedCrossRefGoogle Scholar
  81. 81.
    Poyurovsky M, Shardorodsky M, Fuchs C, et al. Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin: double-blind, placebo-controlled study. Br J Psychiatry 1999; 174: 238–42PubMedCrossRefGoogle Scholar
  82. 82.
    Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1986; 153: 466–76Google Scholar
  83. 83.
    Caligiuri MP, Lohr JB, Bracha HS, et al. Clinical and instrumental assessment of neuroleptic induced parkinsonism in patients with tardive dyskinesia. Biol Psychiatry 1991; 29: 139–48PubMedCrossRefGoogle Scholar
  84. 84.
    Caligiuri MP, Bracha HS, Lohr JB. Asymmetry of neuroleptic-induced rigidity: development of quantitative methods and clinical correlates. Psychiatr Res 1989; 30: 275–84CrossRefGoogle Scholar
  85. 85.
    Hausner RS. Neuroleptic-induced parkinsonism and Parkinson’s disease. J Clin Psychiatr 1983; 44: 13–6Google Scholar
  86. 86.
    Tarsey D. Neuroleptic-induced movement disorders. In: Quinn NP, Jenner PG, editors. Disorders of movement: clinical, pharmacological and physiological aspect. London: Academic Press, 1989: 361–93Google Scholar
  87. 87.
    Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72PubMedCrossRefGoogle Scholar
  88. 88.
    Peabody CA, Warner D, Whiteford HA. Neuroleptics and the elderly. J Am Geriatr Soc 1987; 35: 233–8PubMedGoogle Scholar
  89. 89.
    Jeste DV, Lohr JB, Eastham JH, et al. Adverse effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res 1998; 32: 201–14PubMedCrossRefGoogle Scholar
  90. 90.
    Rajput AH. Drug-induced parkinsonism in the elderly. Geriatr Med Today 1984; 3: 99–107Google Scholar
  91. 91.
    Hoffman WF, Labs SM, Casey DE. Neuroleptic-induced parkinsonism in older schizophrenics. Biol Psychiatry 1987; 22: 427–39PubMedCrossRefGoogle Scholar
  92. 92.
    Caligiuri MP, Rockwell E, Jeste DV. Extrapyramidal side effects in patients with Alzheimer’s disease treated with low dose neuroleptic medication. Am J Geriatr Psychiatr 1998; 6: 75–82Google Scholar
  93. 93.
    Ellis RJ, Caligiuri MP, Galasko D, et al., Extrapyramidal motor signs in clinically diagnosed Alzheimer disease. Alzheimer Dis Assoc Disord 1996; 10: 103–14PubMedCrossRefGoogle Scholar
  94. 94.
    Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 10: 1082–3CrossRefGoogle Scholar
  95. 95.
    Duvoisin RC. Problems in the treatment of parkinsonism. Adv Exp Med Biol 1977; 99: 131–55CrossRefGoogle Scholar
  96. 96.
    Klawans HL, Bergen D, Bruyn GW. Prolonged drug-induced parkinsonism. Confin Neurol 1973; 35: 368–77PubMedCrossRefGoogle Scholar
  97. 97.
    Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatr 1988; 51: 850–4PubMedCrossRefGoogle Scholar
  98. 98.
    Lohr JB, Jeste DV. Neuroleptic-induced movement disorders: acute and subacute disorders. In: Michels R, Cavenar JO, Brodie NKH, et al, editors. Psychiatry. Revised ed. Philadelphia: WB Saunders, 1988: 1–19Google Scholar
  99. 99.
    Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 1999; 19: 322–8PubMedCrossRefGoogle Scholar
  100. 100.
    Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6PubMedCrossRefGoogle Scholar
  101. 101.
    Simpson G, Angus JWS. Arating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9PubMedCrossRefGoogle Scholar
  102. 102.
    Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–15PubMedCrossRefGoogle Scholar
  103. 103.
    Friedman JH. Drug-induced parkinsonism. In. Lang AE, Weiner WJ, editors. Drug-induced movement disorders. Mt Kisco (NY): Futura Publishing Co, 1992: 41–84Google Scholar
  104. 104.
    Sweet RA, Pollock BG, Rosen J, et al. Early detection of neuroleptic-induced parkinsonism in elderly patients with dementia. J Geriatr Psychiatr Neurol 1994; 7: 251–4Google Scholar
  105. 105.
    Caligiuri MP, Lohr JB. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. J Neuropsychiatr Clin Neurosci 1997; 9: 562–7Google Scholar
  106. 106.
    Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 1999; 60Suppl. 8: 21–8PubMedGoogle Scholar
  107. 107.
    DeDeyn P, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946–55CrossRefGoogle Scholar
  108. 108.
    Arnt J, Skarsfeldt T. Do novel antipsychotics gave similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18: 63–101PubMedCrossRefGoogle Scholar
  109. 109.
    Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60Suppl. 10: 5–14PubMedGoogle Scholar
  110. 110.
    Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15: 201–11PubMedCrossRefGoogle Scholar
  111. 111.
    Friedman JH, Ott BR. Should risperidone be used in Parkinson’s disease? J Neuropsychiatry Clin Neurosci 1998; 10: 473–5PubMedGoogle Scholar
  112. 112.
    Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson’s disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56: 556–9PubMedGoogle Scholar
  113. 113.
    World Health Organization. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. World Health Organization heads of centres collaborating on WHO co-ordinated studies on biological aspects of mental illness. Br J Psychiatry 1990; 156: 412CrossRefGoogle Scholar
  114. 114.
    Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic-induced parkinsonism. Drug Saf 1999; 20: 269–75PubMedCrossRefGoogle Scholar
  115. 115.
    Ungvari GS, Chiu HFK, Lam LCW, et al. Gradual withdrawal of long-term anticholinergic antiparkinsonian medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 1999; 19: 141–8PubMedCrossRefGoogle Scholar
  116. 116.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: APA Press, 1994Google Scholar
  117. 117.
    Schooler N, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486–7PubMedGoogle Scholar
  118. 118.
    Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54PubMedCrossRefGoogle Scholar
  119. 119.
    Gill HS. DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377–89PubMedCrossRefGoogle Scholar
  120. 120.
    Sewell DD, Yoshinobu BH, Caligiuri MP, et al. Metoclopramide-associated tardive dyskinesia in hemodialysis patients with diabetes mellitus: two case reports. Gen Hosp Psychiatry 1992; 14: 416–9PubMedCrossRefGoogle Scholar
  121. 121.
    Sewell DD, Kodsi AB, Caligiuri MP, et al. Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994; 36: 630–2PubMedCrossRefGoogle Scholar
  122. 122.
    Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959–1979. Arch Gen Psychiatry 1982; 39: 473–81PubMedCrossRefGoogle Scholar
  123. 123.
    Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophren Bull 1992; 18: 701–15CrossRefGoogle Scholar
  124. 124.
    Kane JM, Woerner M, Weinhold P, et al. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984; 20: 39–41PubMedGoogle Scholar
  125. 125.
    Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521–8PubMedGoogle Scholar
  126. 126.
    Yassa R, Nastase C, Dupont D, et al. Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992; 149: 1206–11PubMedGoogle Scholar
  127. 127.
    Tan CH, Tay LK. Tardive dyskinesia in elderly psychiatric patients in Singapore. Aust N Z J Psychiatr 1991; 25: 191–22CrossRefGoogle Scholar
  128. 128.
    Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a longitudinal study of 266 patients. Arch Gen Psychiatry 1985; 52: 756–65CrossRefGoogle Scholar
  129. 129.
    Jeste DV, Lacro JP, Palmer B, et al., Incidence of tardive dyskinesia in early stages of neuroleptic treatment for older patients. Am J Psychiatry 1999; 156: 309–11PubMedGoogle Scholar
  130. 130.
    Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatr 2000; 61Suppl. 4: 10–4Google Scholar
  131. 131.
    Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716–9PubMedGoogle Scholar
  132. 132.
    Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5PubMedCrossRefGoogle Scholar
  133. 133.
    Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry 1996; 8: 179–82PubMedCrossRefGoogle Scholar
  134. 134.
    Buzan RD. Risperidone-induced tardive dyskinesia [letter]. Am J Psychiatry 1996; 153: 734–5PubMedGoogle Scholar
  135. 135.
    Gwinn KA, Caviness JN. Risperidone-induced tardive dyskinesia and parkinsonism. Mov Disord 1997; 12: 119–21PubMedCrossRefGoogle Scholar
  136. 136.
    Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications: results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50(9): 723–33PubMedCrossRefGoogle Scholar
  137. 137.
    Glazer WM, Morgenstern H, Wagner DR, et al. The Yale Tardive Dyskinesia Study: a prospective incidence study among long-term patients. In. Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press, 1997: 41–55Google Scholar
  138. 138.
    Kennedy PF, Hershon HI, McGuire RJ. Extrapyramidal disorders after prolonged phenothiazine therapy. Br J Psychiatry 1971; 118: 509–18PubMedCrossRefGoogle Scholar
  139. 139.
    Doongaji DR, Jeste DV, Jape NM, et al. Tardive dyskinesia in India: a prevalence study. J Clin Psychopharmacol 1982; 2: 341–4PubMedCrossRefGoogle Scholar
  140. 140.
    Lublin H. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia. Clin Neuropharmacol 1995; 18: 533–51PubMedCrossRefGoogle Scholar
  141. 141.
    Shale H, Tanner C. Pharmacological options for the management of dyskinesia. Drugs 1996; 52: 849–60PubMedCrossRefGoogle Scholar
  142. 142.
    Gardos G, Cole JO. Tardive dyskinesia and anticholinergic drugs. Am J Psychiatry 1983; 140: 200–2PubMedGoogle Scholar
  143. 143.
    Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 (4 Suppl.): 52–6SGoogle Scholar
  144. 144.
    Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenia patients. Am J Psychiatry 1995; 152: 1724–9PubMedGoogle Scholar
  145. 145.
    Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a Task Force report of the American Psychiatric Association. Washington, DC,: APA Press, 1992Google Scholar
  146. 146.
    Lacro JP, Jeste DV. The role of ethnicity in the development of tardive dyskinesia. In: Yassa R, Nair NVP, Jeste DV, editors. Neuroleptic-induced movement disorders. New York (NY): Cambridge University Press, 1997: 298–310Google Scholar
  147. 147.
    Lin KM, Poland RE, Lesser IM. Ethnicity and psychopharmacology. Culture Med Psychiatry 1986; 10: 151–65CrossRefGoogle Scholar
  148. 148.
    Lacro JP, Sewell DD, Warren K, et al. Improving documentation of consent for neuroleptic therapy. Hosp Commun Psychiatry 1994; 45: 176–8Google Scholar
  149. 149.
    National Institutes of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): National Institutes of Mental Health, 1976: 534–7Google Scholar
  150. 150.
    Najib J. Tardive dyskinesia: a review and current treatment options. Am J Ther 1999; 6: 51–60PubMedCrossRefGoogle Scholar
  151. 151.
    Madhusoodanan S, Brenner R, Cohen CI. Risperidone for elderly patients with schizophrenia or schizoaffective disorder. Psychiatr Ann 2000; 30: 175–87Google Scholar
  152. 152.
    Jeste DV, Klausner M, Brecher M, et al. A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. Psychopharmacology 1997; 131: 239–7PubMedCrossRefGoogle Scholar
  153. 153.
    Littrell KH, Johnson CG, Littrell S, et al. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998; 55: 279–80PubMedCrossRefGoogle Scholar
  154. 154.
    Street JS, Tollefson GD, Tohen M, et al. Olanzapine for psychiatric conditions in the elderly. Psychiatr Ann 2000; 30: 191–6Google Scholar
  155. 155.
    Meltzer HY. Atypical antipsychotic drugs. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York (NY): Raven Press Ltd, 1995: 1277–86Google Scholar
  156. 156.
    Barak Y, Wittenberg N, Naor S, et al. Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatr 1999; 40: 320–5CrossRefGoogle Scholar
  157. 157.
    Salzman C, Vacarro B, Lieff J, et al, Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3: 26–33Google Scholar
  158. 158.
    Chengappa KNR, Baker RW, Kreinbrock SB, et al. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatr Neurol 1995; 8: 12–5Google Scholar
  159. 159.
    Sajatovic M. Clozapine for elderly patients. Psychiatr Ann 2000; 30: 170–4Google Scholar
  160. 160.
    Fernandez HH, Friedman JH. The role of atypical antipsychotics in the treatment of movement disorders. CNS Drugs 1999; 11: 467–83CrossRefGoogle Scholar
  161. 161.
    Dalack GW, Becks L, Meador-Woodruff JH. Tardive dyskinesia, clozapine, and treatment response. Prog Neuro-Psychopharmacol Biol Psychiatry 1998; 22: 567–73CrossRefGoogle Scholar
  162. 162.
    Bassitt DP, Neto MRL. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatr Clin Neurosci 1998; 248: 209–11CrossRefGoogle Scholar
  163. 163.
    Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994; 55Suppl. B: 137–8PubMedGoogle Scholar
  164. 164.
    Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7: 70–6PubMedGoogle Scholar
  165. 165.
    Sweet RA, Pollock BG. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 1998; 12: 115–27PubMedCrossRefGoogle Scholar
  166. 166.
    Kahn N, Freeman A, Juncos JL, et al. Clozapine is beneficial for psychosis in Parkinson’s disease. Neurology 1991; 41: 1699–700PubMedCrossRefGoogle Scholar
  167. 167.
    Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disord 1992; 7: 125–31PubMedCrossRefGoogle Scholar
  168. 168.
    Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia [letter]. Lancet 1987; I(8538): 913–4CrossRefGoogle Scholar
  169. 169.
    Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405–7PubMedGoogle Scholar
  170. 170.
    Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43: 868–72PubMedCrossRefGoogle Scholar
  171. 171.
    Barak Y, Swartz M, Shamir E, et al., Vitamin E (α-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatr 1998; 10: 101–5Google Scholar
  172. 172.
    Sajjad SHA. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol 1998; 13: 147–55PubMedCrossRefGoogle Scholar
  173. 173.
    Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacother 1999; 33: 1195–202PubMedCrossRefGoogle Scholar
  174. 174.
    Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Arch Gen Psychiatry 1999; 56: 836–41PubMedCrossRefGoogle Scholar
  175. 175.
    Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990; 147: 445–51PubMedGoogle Scholar
  176. 176.
    Cassady SL, Thaker GK, Tamminga CA. GABAergic treatments for tardive dyskinesia. In: Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press, 1997: 454–69Google Scholar
  177. 177.
    Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophren Bull 1997; 23: 583–609CrossRefGoogle Scholar
  178. 178.
    Anderson U, Haggstrom JE, Bondessan U, et al. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with TD. Mov Disord 1989; 4: 37–46CrossRefGoogle Scholar
  179. 179.
    Tamminga CA, Crayton JW, Chase TN. Improvement in tardive dyskinesia after muscimol therapy. Arch Gen Psychiatry 1979; 20: 888–93Google Scholar
  180. 180.
    Cassady SL, Thaker GK, Moran M, et al. GABA agonist-induced changes in motor, occulomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biol Psychiatry 1992; 32: 192–202CrossRefGoogle Scholar
  181. 181.
    Burner M, Giroux G, L’Heritier C, et al. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunct 1989; 2: 289–96Google Scholar
  182. 182.
    Casey DE, Gerlach J, Magelund G, et al. Gamma-acetylenic GABA in tardive dyskinesia. Arch Gen Psychiatry 1980; 37: 1376–9PubMedCrossRefGoogle Scholar
  183. 183.
    Gerding LB, Labbate LA. Use of clonazepam in an elderly bipolar patient with tardive dyskinesia: a case report. Ann Clin Psychiatr 1999; 11: 87–9Google Scholar
  184. 184.
    Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335–46PubMedCrossRefGoogle Scholar
  185. 185.
    Green P. Tardive dystonia. In Yassa R, Nair NPV, Jeste DV, editors. Neuroleptic-induced movement disorders. Cambridge: Cambridge University Press, 1997: 395–408Google Scholar
  186. 186.
    Kang UJ, Burke RE, Fahn S. Natural history and treatment of tardive dystonia. Mov Disord 1986; 1: 193–208PubMedCrossRefGoogle Scholar
  187. 187.
    Wojcik DJ, Falk WE, Fink JS, et al. A review of 32 cases of tardive dystonia. Am J Psychiatry 1991; 148: 1044–59Google Scholar
  188. 188.
    Yassa R, Nair NPV, Iskander H. A comparison of severe tardive dystonia and severe tardive dyskinesia. Acta Psychiatr Scand 1989; 80: 155–9PubMedCrossRefGoogle Scholar
  189. 189.
    Yassa R, Nair NPV, Ishander H, et al. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatr 1990; 147: 1156–63PubMedGoogle Scholar
  190. 190.
    Sethi KD, Hess DC, Harp RJ. Prevalence of dystonia in veterans on chronic antipsychotic therapy. Mov Disord 1990; 5: 319–21PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Michael P. Caligiuri
    • 1
    • 2
  • Dilip V. Jeste
    • 1
    • 2
  • Jonathan P. Lacro
    • 3
  1. 1.Department of PsychiatryUniversity of CaliforniaSan DiegoUSA
  2. 2.Psychiatry ServicesSan Diego Veterans Affairs Healthcare SystemSan DiegoUSA
  3. 3.Pharmacy ServicesSan Diego Veterans Affairs Healthcare SystemSan DiegoUSA

Personalised recommendations